

Curriculum Vitae

Full Name: Yoshiya Tanaka, MD, PhD

Organization: University of Occupational and Environmental Health, Japan

Position & Title: Professor & Chairman, The First Department of Internal Medicine, School of Medicine, and Dean, Graduate School of Medical Science

Educational background & professional experience

- 1984 MD, University of Occupational and Environmental Health, Japan (UOEH)
- 1988 PhD, Graduate School of Medical Science, UOEH
- 1989- Visiting Fellow in National Cancer Institute, NIH, USA
- 2000- Professor and Chairman, The First Department of Internal Medicine, UOEH
- 2017- Dean, Graduate School of Medical Science, UOEH

Research Interests

Chair of Scientific Committee and past vice president, APLAR
President, Japanese Society of Clinical Immunology (JACI)
Vice President and past president, Japanese Society of Bone and Mineral Research (JSBMR)
Chair of International Affairs, Japanese College of Rheumatology (JCR)
Director board member, Japanese Society of Internal Medicine
Director board member, Japanese Society of Inflammation and Regeneration (JSIR)
Director board member, Japanese Society for Interferon and Cytokine (JSIC)

Publications (Max: 5 titles / in sequence of the latest year)

1. Smolen JS, Pangan AL, Emery P, Eigby W, Tanaka Y, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. *Lancet*

(in press)

2. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. *Lancet* (2018) 392: 222
3. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Camen Morales L, Gonzaga JR, Yakushin S, Ishii T, Veatie S, Arora V, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *New Engl J Med* (2017) 376, 652-62
4. Aletaha D, Bingham III CO, Tanaka Y, et al. Efficacy and safety of sirukumab, an anti-IL-6 cytokine monoclonal antibody, in patients with active rheumatoid arthritis despite anti-TNF therapy: results from the randomized, double-blind, placebo-controlled, global, phase 3 SIRROUND-T study. *Lancet* (2017) 389, 1206-17
5. Tanaka Y, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 β . *Nature* (1993) 361: 79-82